NOD-2 and TLR-4 signaling reinforces the efficacy of dendritic cells and reduces the dose of TB drugs against mycobacterium tuberculosis

Journal of Innate Immunity

Volumn 8, Issue 3, 2016, Pages 228-242

  Khan, Nargis ^a   Pahari, Susanta ^a   Vidyarthi, Aurobind ^a   Aqdas, Mohammad ^a   Agrewala, Javed N ^a  

^a INSTITUTE OF MICROBIAL TECHNOLOGY   (India)

Author keywords

Dendritic cells; Immunomodulation; Isoniazid; Mycobacterium tuberculosis; NOD 2; Rifampicin; TLR 4

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CYTOKINE; ISONIAZID; LIGAND; NITRIC OXIDE; NOD2 LIGAND; RIFAMPICIN; TLR4 LIGAND; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; CARD15 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE; TUBERCULOSTATIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BACTERIAL LOAD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG DOSE REDUCTION; DRUG POTENTIATION; IN VIVO STUDY; INNATE IMMUNITY; LYMPH NODE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUBERCULOSIS; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; IMMUNOLOGY; LUNG; LYMPHOCYTE ACTIVATION; METABOLISM; MICROBIOLOGY; PHYSIOLOGY;

ANIMALS; ANTITUBERCULAR AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELLS, CULTURED; DENDRITIC CELLS; IMMUNITY, INNATE; LUNG; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; NOD2 SIGNALING ADAPTOR PROTEIN; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TUBERCULOSIS;

EID: 84948694731     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000439591     Document Type: Article

References (40)

1. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, Jensen P, Bayona J: Multidrug-resistant and extensively drug-resistant tuberculosis: A threat to global control of tuberculosis. Lancet 2010; 375: 1830-1843.
2. Andersen P, Doherty TM: The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005; 3: 656-662.
3. Howitt MR, Garrett WS: A complex microworld in the gut: Gut microbiota and cardiovascular disease connectivity. Nat Med 2012; 18: 1188-1189.
4. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S, Dai RM, Kiu H, Cardone M, Naik S, Patri AK, Wang E, Marincola FM, Frank KM, Belkaid Y, Trinchieri G, Goldszmid RS: Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342: 967-970.
5. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, Setty M, Leslie CS, Oei Y, Pedraza A, Zhang J, Brennan CW, Sutton JC, Holland EC, Daniel D, Joyce JA: CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013; 19: 1264-1272.
6. Suvas S, Singh V, Sahdev S, Vohra H, Agrewala JN: Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 2002; 277: 7766-7775.
7. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
8. Akira S, Takeda K, Kaisho T: Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675-680.
9. Fremond CM, Yeremeev V, Nicolle DM, Jacobs M, Quesniaux VF, Ryffel B: Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88. J Clin Invest 2004; 114: 1790-1799.
10. Divangahi M, Mostowy S, Coulombe F, Kozak R, Guillot L, Veyrier F, Kobayashi KS, Flavell RA, Gros P, Behr MA: Nod2-deficient mice have impaired resistance to Mycobacterium tuberculosis infection through defective innate and adaptive immunity. J Immunol 2008; 181: 7157-7165.
11. Pandey AK, Yang Y, Jiang Z, Fortune SM, Coulombe F, Behr MA, Fitzgerald KA, Sassetti CM, Kelliher MA: NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis . PLoS Pathog 2009; 5:e1000500.
12. Lupfer C, Thomas PG, Kanneganti TD: Nucleotide oligomerization and binding domain 2-dependent dendritic cell activation is necessary for innate immunity and optimal CD8+ T cell responses to influenza A virus infection. J Virol 2014; 88: 8946-8955.
13. World Health Organization: WHO recommendations, 2007.
14. Buettner M, Meinken C, Bastian M, Bhat R, Stossel E, Faller G, Cianciolo G, Ficker J, Wagner M, Rollinghoff M, Stenger S: Inverse correlation of maturity and antibacterial activity in human dendritic cells. J Immunol 2005; 174: 4203-4209.
15. Marina-Garcia N, Franchi L, Kim YG, Hu Y, Smith DE, Boons GJ, Nunez G: Clathrin- and dynamin-dependent endocytic pathway regulates muramyl dipeptide internalization and NOD2 activation. J Immunol 2009; 182: 4321-4327.
16. Coulombe F, Divangahi M, Veyrier F, de Leseleuc L, Gleason JL, Yang Y, Kelliher MA, Pandey AK, Sassetti CM, Reed MB, Behr MA: Increased NOD2-mediated recognition of Nglycolyl muramyl dipeptide. J Exp Med 2009; 206: 1709-1716.
17. Needham BD, Carroll SM, Giles DK, Georgiou G, Whiteley M, Trent MS: Modulating the innate immune response by combinatorial engineering of endotoxin. Proc Natl Acad Sci USA 2013; 110: 1464-1469.
18. Bohannon JK, Hernandez A, Enkhbaatar P, Adams WL, Sherwood ER: The immunobiology of Toll-like receptor 4 agonists: From endotoxin tolerance to immunoadjuvants. Shock 2013; 40: 451-462.
19. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G: An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999;223:77-92.
20. Barth S, Glick D, Macleod KF: Autophagy: Assays and artifacts. J Pathol 2010; 221: 117-124.
21. MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF: Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci USA 1997; 94: 5243-5248.
22. Riol-Blanco L, Sanchez-Sanchez N, Torres A, Tejedor A, Narumiya S, Corbi AL, Sanchez-Mateos P, Rodriguez-Fernandez JL: The chemokine receptor CCR7 activates in dendritic cells two signaling modules that independently regulate chemotaxis and migratory speed. J Immunol 2005; 174: 4070-4080.
23. Seth S, Oberdorfer L, Hyde R, Hoff K, Thies V, Worbs T, Schmitz S, Forster R: CCR7 essentially contributes to the homing of plasmacytoid dendritic cells to lymph nodes under steady-state as well as inflammatory conditions. J Immunol 2011; 186: 3364-3372.
24. Khader SA, Partida-Sanchez S, Bell G, Jelley-Gibbs DM, Swain S, Pearl JE, Ghilardi N, Desauvage FJ, Lund FE, Cooper AM: Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. J Exp Med 2006; 203: 1805-1815.
25. Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J: Patient adherence to tuberculosis treatment: A systematic review of qualitative research. PLoS Med 2007; 4:e238.
26. Natarajan K, Kundu M, Sharma P, Basu J: Innate immune responses to M. tuberculosis infection. Tuberculosis (Edinb) 2011; 91: 427-431.
27. Huynh KK, Joshi SA, Brown EJ: A delicate dance: Host response to mycobacteria. Curr Opin Immunol 2011; 23: 464-472.
28. Paunescu E: In vivo and in vitro suppression of humoral and cellular immunological response by rifampicin. Nature 1970; 228: 1188-1190.
29. Bellahsene A, Forsgren A: Effect of rifampin on the immune response in mice. Infect Immun 1980; 27: 15-20.
30. Floersheim GL: Suppression of cellular immunity in vivo by rifampicin. Experientia 1973; 29: 1545-1546.
31. Steinman RM, Hemmi H: Dendritic cells: Translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006; 311: 17-58.
32. Holscher C, Atkinson RA, Arendse B, Brown N, Myburgh E, Alber G, Brombacher F: A protective and agonistic function of IL-12p40 in mycobacterial infection. J Immunol 2001; 167: 6957-6966.
33. O'Donnell H, Pham OH, Li LX, Atif SM, Lee SJ, Ravesloot MM, Stolfi JL, Nuccio SP, Broz P, Monack DM, Baumler AJ, McSorley SJ: Toll-like receptor and inflammasome signals converge to amplify the innate bactericidal capacity of T helper 1 cells. Immunity 2014; 40: 213-224.
34. Kaufmann SH: How can immunology contribute to the control of tuberculosis?. Nat Rev Immunol 2001; 1: 20-30.
35. Flynn JL, Chan J: Immunology of tuberculosis. Annu Rev Immunol 2001; 19: 93-129.
36. Jo EK: Innate immunity to mycobacteria: Vitamin D and autophagy. Cell Microbiol 2010; 12: 1026-1035.
37. Castillo EF, Dekonenko A, Arko-Mensah J, Mandell MA, Dupont N, Jiang S, Delgado-Vargas M, Timmins GS, Bhattacharya D, Yang H, Hutt J, Lyons CR, Dobos KM, Dere tic V: Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation. Proc Natl Acad Sci USA 2012; 109:E3168-E3176.
38. Jagannath C, Lindsey DR, Dhandayuthapani S, Xu Y, Hunter RL Jr, Eissa NT: Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat Med 2009; 15: 267-276.
39. Manabe YC, Bishai WR: Latent Mycobacterium tuberculosis - persistence, patience, and winning by waiting. Nat Med 2000; 6: 1327-1329.
40. Wang F, Sambandan D, Halder R, Wang J, Batt SM, Weinrick B, Ahmad I, Yang P, Zhang Y, Kim J, Hassani M, Huszar S, Trefzer C, Ma Z, Kaneko T, Mdluli KE, Franzblau S, Chatterjee AK, Johnsson K, Mikusova K, Besra GS, Futterer K, Robbins SH, Barnes SW, Walker JR, Jacobs WR Jr, Schultz PG: Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. Proc Natl Acad Sci USA 2013; 110:E2510-E2517.